Intellia's first-ever Phase 3 readout for a gene-editing therapy could justify a 50-100% gain if results are strong. Its single-injection treatment for hereditary angioedema, a roughly $2 billion indication, could reach $500 million to $1 billion in peak sales if approved. At a $1.6 billion market cap with about $500 million of net cash, after falling from $177 to $6 on two patient deaths, success would also lift its ATTR Phase 3 program, more than twice HAE's size, due late 2027 to early 2028. x.com